Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0WOJVL
ADC Name	BB-1701
Synonyms	BB1701; BB 1701 Click to Show/Hide
Organization	Baili Sikang Biomedicine (Hangzhou) Co., Ltd.
Drug Status	Phase 1/2
Indication	In total 4 Indication(s) HER2(mu) non-small cell lung cancer [ICD11:2C25] Phase 2 Urothelial cancer [ICD11:2C9Z] Phase 2 HER2(+) solid tumors [ICD11:2A00-2A0Z\|2B50-2F9Z] Phase 1 Solid tumors [ICD11:2A00-2A0Z\|2B50-2F9Z] Phase 1
Structure
	3D MOL	2D MOL
Antibody Name	Undisclosed
Antigen Name	Receptor tyrosine-protein kinase erbB-2 (HER2 exon 20)		Antigen Info
Payload Name	Eribulin		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	Undisclosed
Puchem SID	474492311
Drugbank ID	DB17443

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Objective Response Rate (ORR)	NCT04257110	Phase 1	A first-in-human, open label, multiple dose, dose escalation and cohort expansion phase 1 study to investigate the safety, tolerability, pharmacokinetics and antitumor activities of bb-1701 in subjects with locally advanced/metastatic HER2 expressing solid tumors. Click to Show/Hide

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Objective Response Rate (ORR)	50.00% (all) 70.60% (breast cancer)
Patients Enrolled	Patients with advanced/metastatic HER2-positive solid tumors, who had progressed on, or were intolerant to prior standard therapies, with ECOG PS 2, and measurable disease,.
Administration Dosage	6 dose levels from 0.40 to 2.60 mg/kg Q3W.
*Related Clinical Trial*
NCT Number	NCT04257110	Clinical Status	Phase 1
Clinical Description	A first-in-human, open label, multiple dose, dose escalation and cohort expansion phase 1 study to investigate the safety, tolerability, pharmacokinetics and antitumor activities of bb-1701 in subjects with locally advanced/metastatic HER2 expressing solid tumors.

References

Ref 1	A first in-human, multicenter, open-label, dose-finding phase 1 study of the immune stimulator antibody conjugate NJH395 in patients with nonbreast HER2+ advanced malignancies. J Immunother. Cancer 2020 Volume 8:Suppl 3.